Autonomic Technologies™, Inc., a Redwood City, California-based developer and manufacturer of a microstimulator to treat severe headaches, closed a $38m Series D financing.
The round was led by Edmond de Rothschild Investment Partners (EdRIP), syndicated with Forbion Capital Partners, from Naarden, the Netherlands and existing investors Kleiner Perkins Caufield and Byers, InterWest Partners, Novartis Venture Fund, Aberdare Ventures and the Cleveland Clinic. In conjunction with the funding, Olivier Litzka, Partner at Edmond de Rothschild Investment Partners (EdRIP) and Martien van Osch, Managing Partner at Forbion Capital Partners (Forbion) will join ATI’s Board of Directors.
The company intends to use the capital to fund the ongoing IDE study in the USA, further build out its position in the field of neurostimulation in headache, expanding the launch to other countries in Europe and the clinical evidence base of its minimally invasive treatment into other indications.
Led by Ben Pless, President and Chief Executive Officer, Autonomic Technologies is a medical device company focused on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. The company’s initial product, the Pulsante microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is also under an IDE study in the US for the treatment of chronic cluster headache.
ATI has started commercialization of the Pulsante microstimulator in Europe and established Autonomic Technologies Europe GmbH, a wholly owned subsidiary in Germany, to further expand European commercialization.